Cargando…

Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337659/ https://www.ncbi.nlm.nih.gov/pubmed/28270934 http://dx.doi.org/10.1136/rmdopen-2016-000314corr1

Ejemplares similares

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018)

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
por: Hawley, Samuel, et al.
Publicado: (2019)

Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data
por: Edwards, Christopher J, et al.
Publicado: (2023)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
por: Chen, Jing-Wen, et al.
Publicado: (2022)

Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA
por: Hamann, Philip D H, et al.
Publicado: (2020)

Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
por: Costello, R. E., et al.
Publicado: (2021)

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
por: Dixon, W G, et al.
Publicado: (2009)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Influenza Vaccination of Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
por: Stojanovich, Ljudmila
Publicado: (2006)

Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis
por: Grabner, Michael, et al.
Publicado: (2017)

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
por: Cohen, Stanley, et al.
Publicado: (2022)

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Correction: Cells of the synovium in rheumatoid arthritis. Chondrocytes
por: Otero, Miguel, et al.
Publicado: (2008)

Correction to: Earlier chronotype in patients with rheumatoid arthritis
por: Habers, G. Esther A., et al.
Publicado: (2021)

Correction: Increased autophagy in fibroblast-like synoviocytes leads to immune enhancement potential in rheumatoid arthritis
por: Yang, Ru, et al.
Publicado: (2017)

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Mortality in Rheumatoid Arthritis (RA): factors associated with recording RA on death certificates
por: Molina, Emily, et al.
Publicado: (2015)

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Author Correction: Clonal hematopoiesis in patients with rheumatoid arthritis
por: Savola, Paula, et al.
Publicado: (2021)

Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study)
por: Hernández-Cruz, Blanca, et al.
Publicado: (2022)

Correction to: Association between inflammation and systolic blood pressure in RA compared to patients without RA
por: Yu, Zhi, et al.
Publicado: (2019)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
por: Krasselt, Marco, et al.
Publicado: (2022)

Correction: A Comprehensive Molecular Interaction Map for Rheumatoid Arthritis
por: Wu, Gang, et al.
Publicado: (2010)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Correction to: The impact of different (rheumatoid) arthritis phenotypes on patients’ lives
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Anti-Ro/SSA antibodies in rheumatoid arthritis (RA)
por: Franceschini, F, et al.
Publicado: (2003)

Lysozyme and its biological value in rheumatoid arthritis (RA)
por: Smirnow, J, et al.
Publicado: (2001)

Intestinal anaerobic bacteria in early rheumatoid arthritis (RA)
por: Toivanen, P, et al.
Publicado: (2002)

IL2RA is associated with persistence of rheumatoid arthritis
por: van Steenbergen, H.W., et al.
Publicado: (2015)

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

Rheumatoid Vasculitis: Is It Always a Late Manifestation of Rheumatoid Arthritis?
por: Anwar, Muhammad M, et al.
Publicado: (2019)

Correction to: Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis
por: Choi, Changmin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p1652s3o2nrjc9m3bo9veedkan